Vitamin K–dependent osteocalcin carboxylation limits age‑related hydroxyapatite crystal growth and preserves osteocyte mechanosensitivity

Hypothesis

In aging bone, vitamin K–mediated gamma‑carboxylation of osteocalcin (cOC) directly inhibits hydroxyapatite (HA) nucleation and crystal elongation. When cOC levels fall—due to reduced vitamin K availability or impaired carboxylation—HA crystals enlarge, increasing stiffness and brittleness while altering fluid shear stress in the lacunar‑canicular network and diminishing osteocyte mechanosensitivity. Restoring cOC through vitamin K supplementation will therefore attenuate HA crystal growth, improve osteocyte signaling, and reduce age‑related bone fragility.

Mechanistic Rationale

• Carboxylated osteocalcin possesses a high affinity for calcium phosphate surfaces; its glutamic acid residues bind to nascent HA facets, sterically blocking further ion addition (https://pubmed.ncbi.nlm.nih.gov/1666807/).
• Uncarboxylated osteocalcin (ucOC) lacks these negatively charged groups, showing minimal interaction with HA and thus failing to restrain crystal maturation.
• Age‑related declines in vitamin K status or warfarin‑like interference lower the cOC/ucOC ratio, permitting uncontrolled HA growth (https://pubmed.ncbi.nlm.nih.gov/40794153/, https://pubmed.ncbi.nlm.nih.gov/30315999/).
• Enlarged HA crystals increase matrix stiffness, which dampens fluid flow-induced shear stress on osteocyte processes, lowering nitric oxide and prostaglandin signaling pathways that normally stimulate bone formation and suppress sclerostin (https://pubmed.ncbi.nlm.nih.gov/40794153/).
• Consequently, mechanotransduction defects blunt adaptive remodeling, favoring accumulation of microdamage and fracture risk.

Testable Predictions

1. In vitro: Adding recombinant cOC to simulated body fluid will reduce HA crystal length and thickness measured by transmission electron microscopy, whereas ucOC or osteocalcin lacking glutamic acid residues will not.
2. Ex vivo: Bone slices from aged mice treated with vitamin K2 (menaquinone‑7) will show a higher cOC/ucOC ratio, smaller HA crystals (via nanoscale X‑ray diffraction), and increased osteocyte viability under fluid shear stress compared with vehicle controls.
3. In vivo human trial: A double‑blind, randomized controlled trial of postmenopausal women receiving daily vitamin K2 (180 µg MK‑7) for 12 months will demonstrate:
   • A significant increase in serum cOC and decrease in ucOC (https://pubmed.ncbi.nlm.nih.gov/1666807/).
   • Reduced average HA crystal size in transiliac bone biopsies (measured by TEM or synchrotron‑based small‑angle X‑ray scattering).
   • Improved osteocyte‑derived markers of mechanosensitivity (e.g., lower sclerostin, higher PGE₂ in plasma).
   • Enhanced bone material properties (e.g., increased indentation distance increase via reference point indentation) without changes in areal BMD.
4. Falsification: If vitamin K supplementation fails to alter HA crystal size or osteocyte mechanosensitivity despite raising cOC levels, the hypothesis that cOC directly restrains HA growth would be refuted.

Novel Insight

This hypothesis couples two seemingly separate age‑related alterations—HA crystal enlargement and osteocalcin carboxylation—into a single causative axis where vitamin K–dependent osteocalcin acts as a molecular brake on mineral nucleation. By positioning cOC as a regulator of both matrix nanostructure and osteocyte signaling, it provides a mechanistic bridge that explains why interventions targeting vitamin K may improve bone quality independent of bone density changes.